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Abstract
Objective: To investigate the effects of hemodialysis (HD) and periotoneal dialysis (PD) on oxidative stress in
chronic renal failure patients (CRF).
Methods: 20 HD patients (M/F: 8/12, 36 ± 12 years) and 20 PD patients (M/F: 10/10, 40 ± 8 years) were compared
with 20 end stage renal failure patients (CRF) (M/F: 4/16, 61 ± 13 years).
Results: Thiobarbituric acid reactive substances (TBARS) values were elevated in HD and decreased in PD
compared to CRF (P < 0.05). TBARS-VLDL and TBARS-HDL2 were decreased in HD and PD, compared to CRF
(p < 0.05). TBARS-LDL were higher in HD compared to CRF (p < 0.05). No significant difference in TBARS-HDL3
values between the three groups. Carbonyls were increased in HD (p < 0.05) and PD (p < 0.01) compared to CRF.
Plasma superoxide dismutase activity (SOD) was decreased in HD compared to CRF and PD (P < 0.05). Glutathion
peroxidase activity (GSH-Px) was decreased in HD and PD (P < 0.005), compared to CRF. Decrease in catalase
activity was noted only in PD compared to CRF (P < 0.05). An increase in nitric oxide was noted in HD compared
to CRF (p < 0.05). Albumin concentrations were higher in HD and PD compared to CRF (P < 0.001). Whereas uric
acid concentrations were decreased in HD (P < 0.001) compared to CRF and PD. Bilirubin values were similar in all
groups. Increased values of iron were noted in HD and PD, compared to PD (p < 0.001).
Conclusion: HD and PD aggravate oxidative stress generated by uremia. HD accentuates lipid and protein
peroxidation, while PD aggravates protein oxidation. However, the activity of antioxidant enzymes was altered by
both dialysis treatments.
Introduction
Despite significant progress in dialysis technology, ather-
osclerosis and cardiovascular diseases (CVD) are the
leading causes of morbidity and mortality in patients
receiving renal replacement therapy (RRT). The esti-
mated risk for cardiac events such as myocardial infarc-
tion is 3.5-50 times higher among patients requiring
RRT than in the general population [1]. High rate of
CVD morbidity and mortality in chronic renal failure
(CRF) was attributed to a higher prevalence of both
classical and nontraditional risk factors. Moreover, ure-
mia itself contributes to cardiac pathology: many studies
show that CRF is an independent risk factor for CV
morbidity and mortality even after adjustment for tradi-
tional and nontraditional risk factors [2]. The classical
risk factors for CVD (such as old age, hypertension, dia-
betes, smoking, dyslipidaemia, left ventricular hypertro-
phy, heart failure and physical inactivity) are over-
represented in patients on RRT [2-4].
In recent years, oxidative stress (OS) has been postu-
lated to be an important risk factor for cardiovascular
disorders [5]. OS results from an imbalance between
oxidant production and antioxidant defence mechanisms
with increased levels of pro-oxidants leading to tissue
damage [6]. Antioxidants can be divided into intracellu-
lar and extracellular antioxidants. Intracellular enzymatic
antioxidants are superoxide dismutase (SOD), catalase,
and glutathione peroxidase, which convert substrates
(superoxide anion radicals and hydrogen peroxide) to
less reactive forms. Several extracellular antioxidants,
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any medium, provided the original work is properly cited.such as albumin, bilirubin and urate, prevent free radical
reaction by sequestering transition metal ions by chela-
tion in plasma [6].
Several studies have demonstrated increased oxidative
stress in patients with CRF, including accumulation of
reactive carbonyl compounds as markers of elevated
protein peroxidation [5,7,8], increased concentrations of
thiobarbituric acid-reactive substances and malondialde-
hyde in plasma as markers of high lipid peroxidation
[9-11].
One reason for OS in patients with renal failure is the
underlying disease itself. Renal toxicity and immunologi-
cal disorders of the kidney re s u l ti na ne l e v a t e df o r m a -
tion of reactive oxygen species (ROS) active in the
pathogenesis of kidney disease. However, treatment pro-
cedures were also shown to induce OS. Oxidative stress
is particularly detrimental in patients receiving hemodia-
lysis (HD) because there is massive and repeated at each
dialysis session due to the contact of blood with dialysis
membranes, facing to a chronic deficit in antioxidant
defense system (8). Moreover, Several lines of evidence
have indicated that oxidative metabolism in peripheral
and peritoneal phagocytes is activated during peritoneal
dialysis (PD) with conventional dialysate characterized
by high concentration of glucose, by glucose degradation
products (GDP), and by low pH and high osmolality
[12]. Bioincompatibility of PD solutions seems to play a
central role in the increase of ROS production [13].
Moreover, It had been hypothesized that a deficiency
of vascular nitric oxide (NO) might be involved in the
accelerated atherosclerosis and dramatic cardiovascular
mortality observed in patients with CRF [14]. Endothe-
lial dysfunction defined as the impaired ability of vascu-
lar endothelium to stimulate vasodilation, plays a key
role in the development of atherosclerosis in CRF. The
major cause of the endothelial dysfunction is decreased
bioavailability of NO, a potent biological vasodilator
produced in vascular endothelium from L-arginine by
the endothelial NO synthase (eNOS). Another impor-
tant role of endothelial NO is the protection of the vas-
cular wall from the OS induced by its own metabolic
products and by the oxidation products of lipids and
lipoproteins [15].
Thus, this study was carried out in order to investigate
the effects of hemodialysis (HD) and periotoneal dialysis
(PD) on lipid peroxidation and protein oxidation and
antioxidant defence in patients with chronic renal failure
(CRF).
Subjects and Methods
The study was carried out on 60 CRF patients. They
included 20 end-stage renal failure patients (CRF), 20
HD patients and 20 PD patients (Table 1). In the selec-
tion of the CRF patients, we excluded all those with
systemic disease such as diabetes, liver disorders and
those affected by nephrotic syndrome. None of the
patients were taking lipid-lowering drugs or antioxydant
supplements. The drugs they were using included: cal-
cium channel blockers, vit D, calcium carbonate and
erythropoietin. CRF patients included 20 subjects who
had a mean value of creatinine clearance of 9.2 ± 2.1
ml/min (range 5-13) as calculated from plasma creati-
nine according to Cockroft and Gault formula [16]
[GFR = (140-age) × body weight × 1.23/creatinine. In
women, this value was multiplied by 0.85]. Dietary pro-
tein and phosphate intake were restricted in these
patients. HD patients were on standard bicarbonate HD
using polysulfone membrane. Patients were dialyzed
since 12 to 60 months, three times a week, each session
lasting 4 h. PD patients were in dialysis since 3 to 48
months, using a standard procedure (four exchanges:
three isotonic 1.36% glucose solutions, then a hypertonic
one at 3.86% glucose).
All patients were treated at the Nephrology ward of
the University Hospital of Oran. The purpose of this
study was explained to the subjects and the investigation
was carried out with their consent. The experimental
protocol was approved by the Committee for Research
on Human Subjects of Oran.
Assays
In all patients, blood samples were drawn after a 12-
hours overnight fast by antecubital venipuncture in CRF
and PD patients and by the dialysis fistule in HD
patients. Samples were collected by low speed centrifu-
gation at 3000 × g at 5°C, for 15 min, and were pre-
served with 0.1% Na2 EDTA and 0.02% sodium azide.
Lipids, proteins and apolipoproteins analysis
Triacylglycerols (TG) and total cholesterol (TC) were
determined by colorimetric methods (BioMérieux Kits,
France). Plasma high density lipoprotein-cholesterol
Table 1 Clinical and biochemical characteristics of the
patients
CRF HD PD
Patients N = 20 N = 20 N = 20
Age (years) 61 ± 13 36 ± 12 40 ± 8
Weight (kg) 71.5 ± 8.07 56.71 ± 13.87 65.87 ± 18.22
BMI (Kg/m
2) 2 7±3 2 1±4 2 3±5
Sex ratio (M/F) 4/16 8/12 10/10
Dialysis duration (months) - 12 - 60 3 - 48
Glucose (g. L
-1) 0.90 ± 0.06 0.85 ± 0.02 0.95 ± 0.06
Creatinin (μmol.ml
-1) 221 ± 94 834 ± 47 735 ± 194
Urea (mmol.L
-1) 1 2±4 1 4±1 1 2±0 . 8
Total proteins (g. L
-1) 66 ± 0.6 60 ± 1.2 57 ± 0.9
Data are expressed in mean ± SD. BMI: Body mass index (weight kg/height
m
2). SBP: Systolic blood pressure, DBP: Diastolic blood pressure.
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CHOD-PAP kit after precipitation of the chylomicrons,
very low density lipoprotein cholesterol and Low density
lipoprotein cholesterol (LDL-C) with phosphotungstic
acid and Mg
++ (BioMérieux Kits, SA-France).
Plasma LDL-C was determined enzymatically using the
CHOD-PAP kit after precipitation of LDL. Plasma apo-
lipoproteins (apo) A-I and B were measured by immu-
noturbidimetric method (Human kit, Germany).
Isolation of plasma VLDL-LDL-HDL2 and HDL3
Lipoproteins were isolated by precipitation using MgCl2
and phosphotungstate (Sigma Chemical Company,
France) by the method of Burstein et al., 1970 [17].
HDL2 and HDL3 were separated by precipitation
according to the method of Burstein et al., 1989 [18]
using MgCl2 and dextran sulfate weight 500,000 (Sigma
Chemical Company, France).
Lipid and protein peroxidation
Lipid peroxidation was estimated by measuring thiobar-
bituric acid reactive substances (TBARS) concentrations
according to the method of Quintanilha et al [19], using
tetramethoxypropane (Prolabo) as precursor of malon-
dialdehyde. TBARS was analyzed in plasma and in each
lipoprotein. One milliliter of diluted sample (protein
concentration about 2 mg/ml) was added to 2 ml of
thiobarbituric acid (final concentration, 0.017 mmol/L),
butylated hydroxytoluene (concentration, 3.36 mmol/L)
and incubated for 15 min at 100°C. After cooling and
centrifugation, the absorbance of supernatant was mea-
sured at 535 nm. Data were expressed as mmol of
TBARS produced/ml of plasma.
Oxidized proteins were estimated by measuring carbo-
nyls concentrations according to the method of Levine
et al [20] using the 2.4-dinitrophenylhydrazine (DNPH).
Antioxidant measurements
Superoxide dismutase (SOD; EC 1.15.1.1) and Glu-
tathione peroxidase (GSH-Px; EC 1.11.1.9) were deter-
mined by Cayman Chemical kit. SOD activity was
assessed at 440 nm by measuring the dismutation of
superoxide radicals generated by xanthine oxidase and
hypoxanthine. GSH-Px activity was measured indirectly
by a coupled reaction with glutathione reductase (G-
Red). Oxidized glutathione (GSSG), produced upon
reduction of an organic hydroperoxide by GSH-Px was
recycled to its reduced state by G-Red and NADPH.
The oxidation of NADPH to NADP+ is accompanied by
a decrease in absorbance at 340 nm. Catalase (CAT; EC
1.11.1.6) activity was measured at 25°C using the Aebi
method [21] by measuring the rate of decomposition of
H2O2 at 240 nm. Colorimetric methods were used for
the determination of albumin, urate (Kits Boehringer,
Mannheim, Germany), iron and bilirubin (Biolabo kit,
France). C-Reactive Protein (CRP) was measured by the
immunoturbidimetric method (Fumouze, France).
Determination of plasma nitric oxide (N0)
NO determination was performed using the Griess
reagent (sulfamide and n-naphtyl-ethylene diamine)
(Cortas & Wakid., 1990) [22] method. Plasma was clari-
fied by zinc sulfate sodium and NO3 was then reduced
to NO2 by cadmium overnight at 20°C under shaking.
Samples were added to the Griess reagent and incubated
for 20 min at room temperature. Absorbance was mea-
sured at 540 nm. Sodium nitrite was used for a standard
curve.
Statistical analysis
Statistical analysis was performed using STATISTICA
6.0 (for windows, StatSoft Inc. software, Tulsa, OK,
USA). Data are presented as mean ± standard deviation
(SD). Data normality and the distribution of the vari-
ables were tested by the Kolmogorov-Smirnov test. The
difference between the means from the different groups
was checked by ANOVA adjusted for multiple compari-
sons. Depending on the normality of distribution of
variables, the comparisons between groups were per-
formed using the unpaired Student’s t-test, 1-way analy-
sis of variance (ANOVA) or the Mann-Whitney U-test
when results were nonparametrically distributed.
P < 0.05 was considered statistically significant.
Results
Lipids and apolipoproteins parameters (Table 2)
A significant decrease in TG values was noted in HD
(-52%) and PD (-45%) compared to CRF (p < 0.01),
while no significant difference was noted. No significant
difference was noted in TC values in HD and PD groups
compared to CRF group. However, a significant decrease
in TC values by 31% was noted in PD compared to HD
(p < 0.05).
Table 2 Lipids, apolipoproteins and atherogenic indices
of the study groups
CRF HD PD
TG (mmol.L
-1) 3.11 ± 0.4 1.48 ± 0.62** 1.7 ± 0.42**
TC (mmol.L
-1) 6.02 ± 2.48 6.82 ± 1.29 4.7 ± 1.57 #
HDL-C (mmol.L
-1) 1.29 ± 0.94 1.09 ± 0.41 1.07 ± 0.53
LDL-C (mmol.L
-1) 2.25 ± 0.62 3.76 ± 0.27**# 2.35 ± 0.40
Apo A-I (g. L
-1) 1.07 ± 0.53 1.11 ± 0.14 0.89 ± 0.48
Apo B (g. L
-1) 0.34 ± 0.05 0.27 ± 0.07 0.30 ± 0.04
TC/HDL-C 7.38 ± 0.34 4.88 ± 0.73 * 2.27 ± 0.48**###
LDL-C/HDL-C 2.50 ± 0.94 2.96 ± 0.35 2.59 ± 1.36
Apo AI/Apo B 2.43 ± 0.85 3.89 ± 0.67 3.04 ± 1.75
CRF: End stage chronic renal failure patients. HD: patients on hemodialysis.
PD: Patients on peritoneal dialysis. Data are presented as the mean ± SD. HD
group and PD group vs CRF group # HD group vs PD group. *# (P < 0.05);
**##(P < 0.01); ###(P < 0.001)
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were similar in PD and CRF. However, LDL-C concen-
trations were elevated by 37% in HD compared to PD
(p < 0.05).
Similar values of apo A-I, apo B, HDL-C concentra-
tions, LDL-C/HDL-C and Apo AI/Apo B ratios were
noted in HD, PD and CRF groups. However, values of
TC/HDL-C ratio were decreased by 34% and 69%,
respectively in HD (p < 0.05) and PD (p < 0.01), com-
pared to CRF. Moreover, values of this ratio were
diminished by 53% in PD compared to HD (p < 0.001).
Oxidative status (Table 3)
Compared to CRF, TBARS values were elevated in HD
(P < 0.05) and PD (p < 0.05). A significant decrease in
TBARS-VLDL by 82% and 95% was noted in HD and
PD groups, respectively, c o m p a r e dt oC R Fg r o u p( p<
0.01). TBARS-LDL were significantly higher in HD and
PD groups compared to CRF group (p < 0.05). There
was no significant difference in TBARS-HDL3 values
between the three groups. TBARS-HDL2 values were
decreased by 48% and 74% in HD and PD, respectively,
compared to CRF (p < 0.05). Values were more lower
by 51% in PD compared to HD (p < 0.05).
Carbonyls values were significantly increased by 67%
in HD (p < 0.05) and by 84% in PD (p < 0.01) compared
to CRF. Carbonyls concentrations were more elevated
(+52%) in PD than in HD (p < 0.01).
Antioxidative status (Table 4)
Plasma SOD activity was decreased in HD compared to
CRF (-15%; P < 0.05) and PD (-13%; P < 0.05). Similar
SOD activity was noted in PD and CRF. GSH-Px activity
was decreased by 23% in HD and PD (P < 0.005), com-
pared to CRF. Decrease in catalase activity was noted
only in PD compared to CRF (-22%; P < 0.05) and HD
(-18%; P < 0.05). A significant increase by 26% in NO
concentrations was noted in HD compared to CRF
(p < 0.05).
Albumin concentrations were diminished in HD and
PD compared to CRF (P < 0.05). Uric acid concentrations
were decreased in HD and PD (P < 0.001) compared to
CRF. Bilirubin values were similar in the three groups.
Whereas, an increase by 67% and 59% in iron values was
n o t e di nH Da n dP D ,c o m p a r e dt oP D( p<0 . 0 0 1 ) .C -
Reactive Protein concentrations were higher in HD and
PD groups compared to CRF (p < 0.05).
Discussion
A comparative study was conducted in CRF patients, in
order to evaluate the effect of HD and PD on lipid per-
oxidation, protein oxidation and antioxidant defence.
The case-control studies agree that CRF patients have
increased OS produced by an imbalance between pro-
and anti-oxidant capacities [23-25]. This oxidative stress
is responsible for the peroxidation of macromolecules
such as lipids and proteins causing significant damage.
Several pathophysiologic explanations have been
claimed; some attribute it to malnutrition and hypoalbu-
minemia having in theses cases low availability of
«thiol»; others to «uremic status» itself with solute
retention that may favor their pathogenicity; and others
to the association of comorbid factors such as advanced
age, diabetes, and inflammatory and infectious phenom-
ena [26,27].
Dyslipidemia is one of the main risk factors of cardio-
vascular complications in patients with CRF. In our
study, patients on HD and PD have lower level of
plasma triglycerides, than undialyzed CRF patients.
Total cholesterol, HDL-C, apo A-I and B were
unchanged according to dialysis treatment. However,
HD causes an elevation of LDL-C. These results were
different from our previous investigations in which we
established more elevated TG values in HD patients
treated by a cuprophan membrane [28].
Table 3 Oxidative status in the study groups
CRF HD PD
TBARS (μmol.L
-1) 0.12 ± 0.01 0.23 ± 0.02* 0.18 ± 0.01*
TBARS-VLDL (μmol.L
-1) 0.55 ± 0.02 0.10 ± 0.05** 0.026 ± 0.014**
TBARS-LDL (μmol.mL
1) 0.038 ± 0.002 0.055 ± 0.023* 0.052 ± 0.014*
TBARS-HDL2 (μmol.mL
1) 0.09 ± 0.01 0.047 ± 0.008* 0.023 ± 0.01*#
TBARS-HDL3 (μmol.mL
1) 0.196 ± 0.05 0.105 ± 0.070 0.231 ± 0.049
Carbonyls (μmol.mL
1) 0.3 ± 0.16 0.92 ± 0.15* 1.90 ± 0.10**##
CRF: End stage chronic renal failure patients. HD: patients on hemodialysis.
PD: Patients on peritoneal dialysis. Data are presented as the mean ± SD.
* HD group and PD group vs CRF group # HD group vs PD group.
*#(P < 0.05); **##(P < 0.01)
Table 4 Antioxidative status in the study groups
CRF HD PD
SOD (U.ml
-1) 82.10 ± 1.53 70.08 ± 4.20* 80.12 ± 0.38#
GSH-Px (U.ml
-1) 5.92 ± 0.53 4.12 ± 0.3* 4.08 ± 0.06*
Catalase (U.ml
-1) 85.45 ± 4.74 80.18 ± 1.32 65.78 ± 3.45**#
Nitric oxide (μmol.L
-
1)
22.53 ± 7.24 30.57 ± 8.7* 20.52 ± 1.58
Albumins (g.L
-1) 32.95 ± 0.25 30.78 ± 1.18* 29.50 ± 0.07*
Urate (μmol/L) 513.94 ±
171.61
382.09 ±
66.07***
349.63 ±
167.2***
Bilirubin (μmol/L) 6.29 ± 2.60 5.01 ± 0.60 8.39 ± 6.76
Iron (μmol/L) 33.08 ± 7.71 55.17 ± 1.53 *** 40.59 ± 3.07###
CRP (mg L
-1) 6.5 ± 0.2 8.2 ± 0.2* 8.8 ± 0.8*
CRF: End stage chronic renal failure patients. HD: patients on hemodialysis.
PD: Patients on peritoneal dialysis. Data are presented as the mean ± SD.
* HD group and PD group vs CRF group # HD group vs PD group.
*# (P < 0.05); **(P < 0.01); ***###(P < 0.001)
Mekki et al. Lipids in Health and Disease 2010, 9:93
http://www.lipidworld.com/content/9/1/93
Page 4 of 7The present study demonstrates that HD and PD
cause an increase in oxidative stress. HD and PD leads
to a lipid and protein peroxidation. OS was also
affirmed by the decrease in the activity of antioxidant
enzymes. Peroxidations of LDL have been postulated as
important factors in the development of atherosclerosis.
Increased levels of lipid peroxides are detected in
patients with atherosclerotic disease. Also, the suscept-
ibility of LDL to oxidation in vitro has been associated
with the severity of coronary atheroselerosis in patients
with CVD [29].
The formation of carbonyls is an early marker of pro-
tein oxidation. Carbonyls stress in uremia was related to
decreased removal of chemically modified proteins by
glomerular filtration. Reactive carbonyl compounds
formed by the oxidation of carbohydrates and lipids
may indirectly lead to advanced glycation or lipoxidation
proteins, contributing to the long-term complications
associated with CRF [30].
Free radicals are the source of lipid peroxidation
derived from oxygen, and the first line of defense against
them is SOD. Its function is to catalyse the conversion
of superoxide radicals to hydrogen peroxide (H2O2).
Hence, the decreased SOD activity in HD suggests that
the accumulation of superoxide anion radical might be
responsible for increased lipid peroxidation [6]. More-
over, GSH-Px is responsible for most of the decomposi-
tion of lipid peroxide and may thus protect the cell
from the deleterious effects of peroxides. H2O2 in the
presence of sufficient catalase activity will be converted
to harmless H2Oa n dO 2. In the present investigation,
lower GSH-Px activity was observed in HD and PD.
GSH-Px is an enzyme that scavenges H2O2 and lipid
peroxides [6]. Our result explained the increase in
TBARS levels. In this study, NO concentrations were
elevated in HD patients however PD seems to not alter
their levels. The important role of endothelial NO is the
protection of the vascular wall from the OS induced by
its own metabolic products and by the oxidation pro-
ducts of lipids and lipoproteins [14,15].
Bilirubin, uric acid and plasma albumin concentrations
are the primary defense against OS in extracellular fluids
results [30,31], generated during normal metabolism or
introduced in the body by the consumption of dietary
products rich in antioxidants. Knowing that our HD
patients had a food intake characterized by reduced fruit
and vegetables intake, this unbalanced diet contributes
to a significant oxidative stress. Antioxidants are essen-
tially made by fruit and vegetables that are rich in vita-
mins (A, C, E), trace - elements and other polyphenols.
The determination of plasma iron provides excellent
guidance on the OS status of patients. Iron values were
elevated in HD and PD patients. Iron plays a crucial
role in the initiation and propagation of radical reactions
allowing the formation of hydroxyl radicals (OH°). Iron
also catalyzes the decomposition of lipid peroxides
(ROOH) by transforming them into alkoxyl radicals (RO
°) and peroxyl (ROO°) that amplify the process of lipid
peroxidation. However, iron increase the generation of
oxygen free radicals, leading to the formation of lipid
peroxides [7]. In our study, CRP values were greater
than 5 mg.L
-1 in the CRF group and values were more
elevated in HD and PD. CRP is a prominent product of
the inflammatory response syndrome and a marker of
overall and cardiovascular death in the general popula-
tion as well as in CRF patients [32]. The view has been
brought forward that a chronic inflammatory response
m a yb et h ep r i m a r yc a u s eo fi n creased oxidative stress
in CRF patients [33]. However, it could also be vice
versa. The imbalance between free radical formation
and neutralization in dialysis patients may be the causa-
tive factor for the activation of an inflammatory cascade
by a variety of potential stimulators in uremia and dialy-
sis. A common signaling occurs via generation of oxy-
gen-free radicals, activationo ft h et r a n s c r i p t i o nf a c t o r
nuclear factor-kappa B (NF-B) and induction of a num-
ber of genes such as adhesion molecules, cytokines, and
chemokines. The result may be IL-6 stimulated produc-
tion of CRP by the liver [32].
However, the problem to be addressed is to know why
HD and PD aggravate oxidative stress of uremic
patients. HD further worsens this condition mainly by
losses of hydrophilic unbound small molecular weight
substances such as vitamin C, trace elements and
enzyme regulatory compounds. Moreover, inflammatory
state plays a critical role in the production of oxidants
contributing further to aggravate the pro-oxidant status
of uremic patients [7,8,30,31]. Dialyser interactions and
the microbial contamination or pyrogen content of the
dialysate, the possible prooxidant effect of a number of
metabolites, found at high concentrations in the
patients’ plasma, including uric acid have been suggested
as the three major causes of OS. In the HD population,
as the interaction between dialysis membranes and
blood neutrophils can trigger the release of oxygen-free
radicals and oxidizing agents, such as superoxide anion,
hydrogen peroxide and myeloperoxidase. In turn, these
molecules contribute to the oxidation of lipid by pro-
ducts, proteins and nucleic acids. This oxidation has
several pathophysiological consequences, including
enhanced atherogenicity of Ox-LDL, as well as acceler-
ated demise of circulating erythrocytes, leading to a
shorter life span [34,35].
Infections occurring in peritoneal dialysis patients are
more frequent than in general population. Risk factors
in those patients are multiple such as immune deficit
and cutaneous port of entry. Our patients were treated
by a conventional peritoneal dialysis considered as
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conventional glucose-based peritoneal dialysis fluids
plays a central role in the pathogenesis of the functional
and structural changes of the peritoneal membrane. Low
pH, high glucose concentration and heat sterilization
represent major factors of low biocompatibility [31].
GDP are formed during heat sterilization (glycoxidation)
and storage. GDP can bind protein and form AGEs
(Advanced Glycation End-products), which can also
result from the binding of glucose to free NH2 residues
of proteins (glycation).
In conclusion, this study demonstrates that hemodialy-
sis and peritoneal dialysis exacerbate oxidative stress
generated by uremia. HD and PD accentuate lipid and
protein peroxidation, moreover, the activity of antioxi-
dant enzymes was altered by both dialysis treatment
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